Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma: Erratum

In the article, “Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma”, which appeared in the pages 175-180, Issue 3, Vol. 21 of The Saudi Journal of Gastroenterology,[1] in the Abstract section, the percentages “17%” and “28%” in the sentence “Complete response (CR), objective response (OR), disease control (DC), and progressive disease (PD) rates were 11%, 24%, 17%, and 47%, respectively, in the DEB = TACE group compared with 4%, 32%, 28%, and 36%, respectively, in the c-TACE group.” should be written as “53%” and “64%” respectively.

In the Patients and Methods section, the word “non-HCC” in the first sentence “This study retrospectively compares the efficacy and safety profile of DEB-TACE with that of C-TACE in the management of non-HCC.” should be written as “nonresectable HCC”.

In the Patients and Methods section, the words “pre- and postclinical” in the third sentence “All patients had pre- and postclinical and laboratory evaluation as well as cross-sectional imaging with triphasic computed tomography (CT) or magnetic resonance (MR) of the liver prior to and following the procedure to assess for tumor response.” should be replaced with the word “clinical”.

These have now been corrected and reposted online.